Amylyx Pharmaceuticals (AMLX) large deep ITM call buyer of 2100 October $7.50 calls at $17.00 aggressive offers, synthetic long stock position. AMLX a recent IPO from January, small cap bio and is breaking out above a coiled range at the 24 level this month. Potential to see its old highs at 33 from here. The company recently announced FDA plan to reconvene advisory committee to review AMX0035 NDA for the treatment of ALS on September 7, 2022.